ProShare Advisors LLC Lowers Stock Holdings in Perrigo Company plc $PRGO

ProShare Advisors LLC reduced its position in Perrigo Company plc (NYSE:PRGO) by 6.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,237,768 shares of the company’s stock after selling 90,109 shares during the quarter. ProShare Advisors LLC owned about 0.90% of Perrigo worth $27,565,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of PRGO. Geneos Wealth Management Inc. increased its holdings in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares during the last quarter. Huntington National Bank increased its stake in Perrigo by 237.8% in the second quarter. Huntington National Bank now owns 1,054 shares of the company’s stock valued at $28,000 after acquiring an additional 742 shares during the last quarter. Hantz Financial Services Inc. raised its position in Perrigo by 101.0% during the second quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock valued at $33,000 after purchasing an additional 620 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Perrigo by 89.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock worth $38,000 after purchasing an additional 838 shares in the last quarter. Finally, Kestra Investment Management LLC boosted its holdings in shares of Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after purchasing an additional 642 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Price Performance

PRGO opened at $14.40 on Wednesday. The company’s 50-day simple moving average is $14.11 and its two-hundred day simple moving average is $18.40. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.44 and a current ratio of 2.51. The stock has a market capitalization of $1.98 billion, a P/E ratio of -37.89, a P/E/G ratio of 1.29 and a beta of 0.39. Perrigo Company plc has a 52-week low of $12.17 and a 52-week high of $30.93.

Analysts Set New Price Targets

Several analysts have issued reports on PRGO shares. Wall Street Zen lowered shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research lowered Perrigo from a “hold” rating to a “strong sell” rating in a research note on Friday, November 7th. Argus upgraded Perrigo to a “hold” rating in a research report on Wednesday, January 14th. JPMorgan Chase & Co. decreased their price target on Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Finally, Canaccord Genuity Group lowered their price objective on Perrigo from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $20.33.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.